# US 11,439,653 B1 · Fospropofol formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,653 B1
- Document ID: US11439653B1
- Status: Granted
- Kind: B1
- Application number: 17/466,016
- Filed: 2021-09-03
- Published: 2022-10-06
- Granted: 2022-09-13
- Earliest claimed: 2021-03-30
- Assignees: Epalex Corporation
- Applicants: Epalex Corporation
- Inventors: Steven L. Krill; Feng-Jing Chen
- Web page: https://patentgrep.com/patent/US11439653B1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides pharmaceutical compositions for oral administration of fospropofol, or pharmaceutically acceptable salts of fospropofol, as well as methods of oral administration of fospropofol.

## Claims

### Claim 1

A pharmaceutical dosage form for oral administration comprising fospropofol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable acid wherein the mole ratio of fospropofol, or a pharmaceutically acceptable salt thereof, to the pharmaceutically acceptable acid is 3:1 or less.

### Claim 2 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein said pharmaceutical dosage form comprises fospropofol.

### Claim 3 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein said pharmaceutical dosage form comprises a pharmaceutically acceptable salt of fospropofol.

### Claim 4 (depends on 3)

The pharmaceutical dosage form according to claim 3, wherein said pharmaceutically acceptable salt of fospropofol is fospropofol disodium.

### Claim 5 (depends on 1)

The pharmaceutical dosage form according to claim 1, in the form of a tablet, capsule, or softgel.

### Claim 6 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the mole ratio of fospropofol, or a pharmaceutically acceptable salt thereof, to the pharmaceutically acceptable acid is 2:1 or less.

### Claim 7 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the mole ratio of fospropofol, or a pharmaceutically acceptable salt thereof, to the pharmaceutically acceptable acid is 1.5:1 or less.